Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (55)
July 26, 2004
- Maurer's Healthcare Insight (54)
May 17, 2004
- Maurer's Healthcare Insight (53)
April 19, 2004
- Maurer's Healthcare Insight (52)
March 22, 2004
- Maurer's Healthcare Insight (51)
March 1, 2004
- Maurer's Healthcare Insight (50)
February 16, 2004
- Maurer's Healthcare Insight (49)
January 26, 2004
- Maurer's Healthcare Insight (48)
December 1, 2003
- Maurer's Healthcare Insight (47)
November 3, 2003
- Maurer's Healthcare Insight (46)
October 6, 2003
- Maurer's Healthcare Insight (45)
September 8, 2003
- Maurer's Healthcare Insight (44)
August 11, 2003
- Maurer's Healthcare Insight (43)
July 14, 2003
- Maurer's Healthcare Insight (42)
June 16, 2003
- Maurer's Healthcare Insight (41)
May 19, 2003
- Maurer's Healthcare Insight (40)
April 28, 2003
- Maurer's Healthcare Insight (39)
April 14, 2003
- Maurer's Healthcare Insight (Special)
March 24, 2003
- Maurer's Healthcare Insight (Special)
March 17, 2003
- Maurer's Healthcare Insight (38)
February 17, 2003
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…